Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Lupus Nephritis (LN) Clear all

Conditions: Lupus Nephritis (LN)
Interventions: Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
Interventions: zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: Miltenyi Biomedicine GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Lupus Nephritis
Interventions: Ixazomib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 12
States / cities: La Jolla, California • Upland, California • Port Charlotte, Florida + 9 more

Conditions: Lupus Nephritis
Interventions: ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c.; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 25
States / cities: Birmingham, Alabama • La Palma, California • Orange, California + 20 more

Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
Interventions: ALXN2050, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Huntsville, Alabama • Loma Linda, California • Northridge, California + 7 more

Conditions: Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Cutaneous Lupus Erythematosus (CLE)
Interventions: Not listed
Lead sponsor: Lupus Foundation of America; Other
Eligibility: Not listed
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2050
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Lupus Nephritis
Interventions: secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more

Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy
Interventions: Ravulizumab, Placebo, Background Therapy; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 17
States / cities: San Dimas, California • Santa Monica, California • South Gate, California + 13 more

Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions: rapcabtagene autoleucel; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 17
States / cities: Birmingham, Alabama • San Bernardino, California • San Francisco, California + 11 more

Conditions: IgA Nephropathy (IgAN), IgA Vasculitis, Idiopathic Immune Complex Glomerulonephritis, C3 Glomerulopathy, Membranous Nephropathy, Focal and Segmental Glomerulosclerosis, Minimal Change Disease, Anti-Neutrophilic Cytoplasmic Antibody-GN (ANCA), Lupus Nephritis (LN), Alport Syndrome, Infection-related or Post-infectious Glomerulonephritis, Idiopathic Nephrotic Syndrome (INS)
Interventions: Not listed
Lead sponsor: Pediatric Nephrology Research Consortium; Other
Eligibility: Up to 18 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Boston, Massachusetts • Cincinnati, Ohio

Conditions: Lupus Nephritis, Primary Membranous Nephropathy
Interventions: NKX019, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Nkarta, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 17
States / cities: Little Rock, Arkansas • Tustin, California • Gainesville, Florida + 14 more

Conditions: Lupus Nephritis
Interventions: Obecabtagene autoleucel; Biological
Lead sponsor: Autolus Limited; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: New York, New York • Syracuse, New York • Houston, Texas + 1 more

Conditions: Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis
Interventions: Tafasitamab, Fludarabine phosphate, Cyclophosphamide, Tafasitamab and NK cells; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Lupus Nephritis
Interventions: Ianalumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Orchard Park, New York

Conditions: Lupus Nephritis
Interventions: Felzartamab; Drug
Lead sponsor: HI-Bio, A Biogen Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: La Jolla, California • San Francisco, California • Stanford, California + 9 more

Conditions: Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions: ALLO-329, Cyclophosphamide, Fludarabine; Genetic · Drug
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 17
States / cities: Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 14 more

Conditions: IgAN, LN, MN, C3G
Interventions: OMS721 (narsoplimab); Biological
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more

Conditions: IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
Interventions: ADX-097; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 16 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Hollywood, Florida • Lawrenceville, Georgia • Orangeburg, South Carolina

Conditions: Lupus Nephritis (LN)
Interventions: Atacicept, Placebo; Drug
Lead sponsor: Vera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 26
States / cities: Huntsville, Alabama • La Jolla, California • La Palma, California + 19 more

Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions: CC-97540, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 16 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 41
States / cities: Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 28 more

Conditions: Lupus Nephritis (LN)
Interventions: Lupus Nephritis (LN) Care Pathway; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lupus Nephritis (LN)
Interventions: Vonsetamig, Odronextamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: San Francisco, California • Gainesville, Florida • Rochester, Minnesota + 1 more

Conditions: Lupus Nephritis (LN)
Interventions: C-CAR168; Biological
Lead sponsor: AbelZeta Inc.; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19, Cell Therapy, Lupus, Lupus Nephritis (LN)
Interventions: CART19; Biological
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 10 Years to 29 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Dapagliflozin in Active Lupus Nephritis

US Zamto-cel Autoimmune Diseases

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Research Accelerated by You Lupus Registry

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort Study

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Lupus Nephritis Care Pathway

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus